C.M. Bidwell & Associates’s Immunovant IMVT Stock Holding History

C.M. Bidwell & Associates’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-735	Closed	-$34K	–	530
2020 Q4	$34K	Buy	+735	New	+$34K	0.03%	314

Other funds holding IMVT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

C.M. Bidwell & Associates's IMVT Position: Q1 2021 in Review

C.M. Bidwell & Associates sold out of Immunovant (IMVT) in Q1 2021, closing a stake of 735 shares — an estimated $34K sold.

C.M. Bidwell & Associates first reported a position in IMVT in Q4 2020 and held it in 1 quarter. The position peaked at $34K in Q4 2020. 120 funds tracked by Wall St. Rank hold IMVT as of Q1 2021.

C.M. Bidwell & Associates reported no remaining Immunovant position as of Q1 2021 after selling out during the quarter.
C.M. Bidwell & Associates sold 735 Immunovant shares in Q1 2021, an estimated $34K.
C.M. Bidwell & Associates first reported a position in Immunovant in Q4 2020 and held it in 1 quarter.
C.M. Bidwell & Associates's Immunovant position peaked at $34K in Q4 2020.
120 funds tracked by Wall St. Rank held Immunovant as of Q1 2021.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2021, filed 14 May 2021.